New recommendations by scientific societies about late-onset hypogonadism
ISA, ISSAM, EAU, EAA and ASA publish in European Urology
Arnhem, 04 December 2008 - The January issue of European Urology, the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations. LOH is a clinical and biochemical syndrome associated with advancing age and characterized by typical symptoms and a deficiency in serum testosterone levels.
Late-onset hypogonadism (LOH) is caused by a decline in gonadal production of androgens in males that occurs with aging. Data indicate that a significant percentage of men over age 60 have serum testosterone levels that are below the lower limits of young adult men (i.e., those age 20–30 yr). Sexual dysfunction - including erectile dysfunction (ED), decreased libido, difficulty achieving orgasm, and decreased penile sensation - is usually the presenting complaint, although fatigue, depressed mood, and decreased muscle mass are other common symptoms.
Because demographic data demonstrate that the percentage of the population in older age groups is increasing worldwide, LOH is becoming a topic of increasing interest and debate throughout the world. The past decade has brought evidence that androgen treatment benefits hypogonadal men, and recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men.
In view of the growing interest from practitioners in the testosterone treatment of older men, the International Society of Andrology (ISA), the International Society for the Study of the Aging Male (ISSAM), the European Association of Urology (EAU), the European Academy of Andrology (EAA), and the American Society of Andrology (ASA) convened meetings of a writing group with expert representatives from each of the societies. They met in Tampa, Florida, in 2008 to revise the recommendations on the “Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism” originally published by the ISA, ISSAM, and EAU in 2005.
The current recommendations provide updated evidence-based information for clinicians who diagnose and treat patients with LOH. These guidelines are available in the January 2009 issue of European Urology.
# # #
Notes to Editors:
The article “Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations”, by Christina Wang, Eberhard Nieschlag, Ronald Swerdloff, Hermann M. Behre, Wayne J. Hellstrom, Louis J. Gooren, Jean M. Kaufman, Jean-Jacques Legros, Bruno Lunenfeld, Alvaro Morales, John E. Morley, Claude Schulman, Ian M. Thompson, Wolfgang Weidner, and Frederick C.W. Wu is being published in European Urology 55 (2009) 121–130, DOI:10.1016/j.eururo.2008.08.033. Copies for members of the media are available by contacting the Elsevier press office at firstname.lastname@example.org.
About the European Association of Urology (EAU)
The European Association of Urology (EAU) represents more than 16,000 urology professionals across Europe and worldwide. Its mission is to raise the level of urological care in Europe. The EAU has special sections on the Internet, such as Uroweb and Urosource, which allow for direct communication. European Urology, produced by the EAU, has been a respected urological forum for over 20 years, and is currently read by more than 9,000 urologists across the globe. With an impact factor of 5.634, the journal has become the leading scientific publication in the field of urology.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+31 20 485 3747